Matthew Mossanen, MD
Urology · Boston, MANPI 1508180241
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Urogen Pharma, Inc. at 25.5% of the total.
Across 31 payments — averaging $441.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogen Pharma, Inc.$3K
- Medtronic$3K
- Intuitive Surgical$2K
- Astellas Pharma US Inc$2K
- Olympus Medical Systems Corporation$2K
- Fennec Pharmaceuticals, Inc.$1K
- plus $487 from 3 others
Across 1 payment — averaging $15,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$15K
What the payments were for
- Consulting fees$6,32046%
- Speaking & faculty fees$3,12523%
- Travel & lodging$1,66812%
- Food & beverage$2,53819%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogen Pharma, Inc. | 5 | $3,484 |
| Medtronic | 5 | $2,975 |
| Intuitive Surgical | 8 | $2,157 |
| Astellas Pharma US Inc | 2 | $1,938 |
| Olympus Medical Systems Corporation | 1 | $1,620 |
| Fennec Pharmaceuticals, Inc. | 6 | $1,026 |
| BD | 2 | $419 |
| AstraZeneca | 1 | $35 |
| Photocure Inc | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JELMYTO$3,276
- PADCEV$1,938
- OES CHOLEDOCHOFIBERSCOPE$1,620
- Da Vinci Surgical System$1,368
- DA VINCI SP$608
- FYARRO$589
- Pedmark$244
- ARISTA$214
- Surgiphor$205
How this compares
$13,686 in reported general payments places this provider in the 85th percentile of 327 urology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 18 | $275 |
| Finasteride | 14 | $106 |
Paid to pharmacies, not to this prescriber.
Other urology in Boston
- Christopher CutieBoston$3.5M
- Brian EisnerBoston$424K
- Stephen DretlerBoston$298K
- Tony LuongoBoston$265K
- Ricardo MunarrizBoston$118K
- Mehrdad AlemozaffarBoston$95K
- Adam KibelBoston$92K
- Ruslan KoretsBoston$86K
- Adam FeldmanBoston$74K
- William BoysenBoston$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.